Localization of Radiolabeled Chemotactic Peptide at Focal Sites of *Escherichia coli* Infection in Rabbits: Evidence for a Receptor-Specific Mechanism

John W. Babich, Ronald G. Tompkins, Wendy Graham, Sandra A. Barrow and Alan J. Fischman
Division of Nuclear Medicine of the Department of Radiology, and the Trauma Service of the Department of Surgery, Massachusetts General Hospital and Shriners Burns Institute, Boston, Massachusetts

The infection imaging properties of a high-affinity $^{99m}$Tc-labeled chemotactic peptide receptor agonist (N-formyl-methionyl-leucyl-phenylalanine-lysine; N-For-MLF) were compared with a low-affinity agonist (N-Acetyl-MLF; N-Ac-MLF), a moderate-affinity antagonist (N-isobutylxocarbonyl-MLF; N-iBoc-MLF) and non-specific imaging imaging agents. **Methods:** All peptides were prepared by solid-phase methods and purified by high-performance liquid chromatography. The products were assayed in vitro for N-formyl-methionyl-leucyl-phenylalanine receptor binding and superoxide production. Three types of studies were performed in rabbits with *Escherichia coli* infection: (Study A) Four groups of six animals were co-injected with $^{99m}$Tc-N-For-MLF-hydrazinonicotinamide (N-For-MLF-HYNIC) plus $^{111}$In-immunoglobulin G, $^{111}$In-red blood cells or $^{111}$In-diethylene triamine pentaacetic acid. (Study B) Three groups of six rabbits were co-injected with $^{111}$In-leukocytes plus $^{99m}$Tc-N-For-MLF-HYNIC, $^{99m}$Tc-N-Ac-MLF-HYNIC or $^{99m}$Tc-N-iBoc-MLF-HYNIC. (Study C) Two groups of six rabbits were injected with $^{99m}$Tc-N-For-MLF-HYNIC and $^{111}$In-leukocytes and with without an excess of antagonist. In all studies, the radiopeptides were injected 24 hr after infection and dual photon ($^{99m}$Tc and $^{111}$In) gamma camera images were acquired at 2–3 and 16–18 hr later. Target-to-background (T/B) ratios were calculated for regions of interest drawn over the infected and contralateral normal tissue. **Results:** N-For-MLF, N-Ac-MLF and N-iBoc-MLF had $EC_{50}$s for receptor binding of 2.0, 830 and 150 nM, respectively. The corresponding $EC_{50}$s for superoxide production were 20.0, $\sim 10^3$ and $>10^3$. Study A demonstrated that the T/B for $^{99m}$Tc-N-For-MLF-HYNIC was higher than for any of the non-specific imaging agents ($p < 0.001$), and $^{111}$In-immunoglobulin G had a higher T/B ratio than $^{111}$In-diethylene triamine pentaacetic acid ($p < 0.01$) or $^{111}$In-red blood cells ($p = NS$). Study B showed that $^{99m}$Tc-N-For-MLF-HYNIC had a higher T/B ratio than the other peptides ($p < 0.001$). $^{111}$In-leukocytes and $^{99m}$Tc-N-iBoc-MLF-HYNIC had comparable T/B ratios, which were higher than for $^{99m}$Tc-N-Ac-MLF-HYNIC ($p < 0.05$). Study C demonstrated that coinjection with an antagonist resulted in a significant reduction in the T/B ratio for $^{99m}$Tc-N-For-MLF-HYNIC ($p < 0.001$), but did not affect the T/B ratio for $^{111}$In-leukocytes. **Conclusion:** Nonspecific mechanisms contribute minimally to the localization of $^{99m}$Tc-chemotactic peptide analogs at sites of infection and the majority of the accumulation appears to be receptor mediated. Also, chemotactic peptide receptor antagonists can be used for injection imaging. These results provide important new insights for future radio-pharmaceutical development.

**Key Words:** agonist; antagonists; peptide; chemotactic infection

J Nucl Med 1997; 38:1316–1322

Leukocyte migration to focal sites of inflammation is mediated by a variety of chemotactic agents. The tri-peptide, N-formyl-methionyl-leucyl-phenylalanine (For-MLF), is one of the most potent chemoattractants, and a distinct class of receptors for this peptide has been identified on white blood cells (WBCs) (1–3). These receptors are present on both polymorphonuclear leukocytes (PMNs) and mononuclear phagocytes. As cells respond to the chemoattractant gradient, the affinity of the receptors decreases as additional receptors are expressed (4–6). Previous studies have demonstrated that many synthetic analogs of this peptide bind to neutrophils and macrophages with equal or greater affinity compared to the native peptide (7–9). Based on this information, we hypothesized that chemotactic peptide analogs, which can be readily radiolebelled with radionucleides suitable for external imaging, might be effective agents for the rapid localization of focal sites of inflammation.

Recent studies in our laboratory have demonstrated that $^{111}$In- and $^{99m}$Tc-labeled For-MLF analogs retain biological and receptor binding activity and can be used for the rapid identification of focal sites of infection in rats and rabbits (7,10). In these studies, the $^{99m}$Tc-labeled peptides yielded images with extraordinarily high target-to-background (T/B) ratios; much higher than the values measured with co-injected $^{111}$In-leukocytes (8) or human polyclonal immunoglobulin G (IgG) (11). In addition, the peptides can be radiolebelled with $^{99m}$Tc at extremely high specific activities (12). At these specific activities excellent quality images were obtained at concentrations of peptide, which are far below the levels that produce significant reductions in peripheral leukocyte counts in rabbits or monkeys (8,12). In studies of burned rabbits with and without infection, we demonstrated that peptide localization is relatively infection selective (13).

Although these studies indicate that $^{111}$In- and $^{99m}$Tc-labeled chemotactic peptides accumulate at sites of infection with high T/B ratios, receptor specificity has not been completely established and a significant amount of localization could be due to nonspecific processes, such as increased tissue permeability, blood pool or blood flow characteristics of inflammatory lesions, or characteristics of the peptides that are not related to For-MLF receptor binding. The experiments described in this study were designed to address these issues. In these studies, New Zealand white rabbits were infected with *Escherichia coli*, co-injected with various combinations of radiopeptides and imaged 2–3 and 16–18 hr later.

**MATERIALS AND METHODS**

For-MLF, N-formyl-norleucyl-leucyl-phenylalananyl-norleucyl-tyrosyl-lysine (For-Nle-LP-Nle-YK), phosphor 12-myristate 13-acetate and cytochalasin B were purchased from Sigma Chemical Co. (St. Louis, MO). For-$^{3}$HMLF (60 Ci/mmol), $^{99m}$TcO$_4^{-}$ ($^{99m}$Mo/$^{99m}$Tc-generator), $^{111}$In-diethylene triamine pentaacetic acid (DTPA) and stannous glucoheptonate (Glucoscan) were obtained from DuPont (Bilerica, MA). Indium-111-oxide was obtained from...
Peptide Synthesis
N-formyl-methionyl-leucyl-phenylalanine-lysine (N-For-MLFK), N-acetyl-MLFK (N-Ac-MLFK) and isobutylloxycarbonyl-MLFK (iBoc-MLFK) were synthesized and purified by standard solid-phase techniques (14,15), as previously described (8–13). Hydrazinonicotinamide (HYNIC)-derivatized chemotactic peptides, N-For-MLFK-HYNIC, N-Ac-MLFK-HYNIC and iBoc-MLFK-HYNIC were prepared by reacting the e amino group of the C-terminal lysyl peptides with succinimidyl-6-t-Boc-hydrazinopryridine-3-carboxylic acid. The t-Boc group was removed by stirring the product with TFA containing p-cresol for 15 min at 20°C. The products were purified by preparative reverse-phase HPLC on a 2.5 × 50 cm Whatman ODS-3 column eluted with a gradient of water/acetone/trifluoroacetic acid. Chemical purity was evaluated by thin-layer chromatography (TLC), high-performance liquid chromatography (HPLC), UV spectroscopy, mass spectroscopy and amino acid analysis. Further details on the preparation of HYNIC derivatized chemotactic peptides have been reported (7).

Receptor Binding
Isolated human neutrophils (PMNs, 8 × 10^5) were incubated in phosphate buffered saline containing 1.7 mM KH2PO4, 8.0 mM Na2HPO4, 0.117 M NaCl, 0.15 mM CaCl2, 0.5 mM MgCl2 and 1.0 mM phenylmethylsulfonyl fluoride (pH 7.4) (incubation buffer) at 24°C for 45 min in a total volume of 0.15 ml in the presence and absence of concentrations of test peptide and 15 nM For-[3H]-MLFK (16). The cells were then filtered onto glass fiber disks and washed with 20 ml of ice-cold incubation buffer. The filters were placed in scintillation vials with 10 ml of Safety-Solve and cell-associated radioactivity was measured by liquid scintillation spectroscopy. Specific binding was defined as total minus nonspecific binding. Nonspecific binding was defined as the amount of residual radioactivity bound in the presence of 10 μM unlabeled For-MLFK and was ~10% of total binding.

Superoxide Release
Superoxide release by human PMN’s was measured by monitoring superoxide dismutase-inhibitable reduction of ferricytochrome C (extinction coefficient: 29.5 mmol/liter/cm) as previously (17). Briefly, isolated human cells were incubated with Hanks’ balanced salt solution alone or with increasing concentrations of the peptide analogs, For-MLF or For-Nle-MLF-IY (range: 1 nM to 1 μM) in the presence of 10 μM cytochalasin B plus or minus superoxide dismutase (50 mg/ml) at 37°C for 10 min followed by spectrophotometric measurement of ferricytochrome C reduction.

Radiochemical Preparation
Technetium-99m-Labeled Chemotactic Peptides. A 99mTc generator was eluted ~5 h after a previous elution to yield ~500 mCi of 99mTcO4-. A typical elution contained ~3 nM of 99mTc; the 99mTc to 99mTc ratio was ~1:5:1 and specific activity was >100,000 mCi/μmol. Technetium-99m-glucoheptonate (99mTc-Gluco) was used to provide the Tc(V) o xo species for radiolabeling HYNIC-conjugated peptides (18). Technetium-99m-gluco was prepared by adding ~300 mCi of 99mTcO4- in saline (~2.5 ml) to freeze-dried kits. The radiochemical purity of the product was >95% by ITLC-sg using both acetone and saline as mobile phase solvents. The HYNIC-derivatized chemotactic peptides (~200 μg), were dissolved in 200 μl of dimethyl sulfoxide and diluted to 20 μg/ml with 50 mM acetate buffer, pH 5.2. The peptide solution (0.5 ml) was placed in a clean glass vial, 99mTc-gluco (0.5 ml, ~75 mCi) was added and the mixture was vortexed and allowed to stand at room temperature for 1 hr. Peptide labeling was monitored by ITLC-sg using three solvent systems: acetone, saline and acetone: water (9:1). Radiolabeled peptide was purified by reverse-phase HPLC on a C-18 column (5 μ, 4.5 × 46 mm) eluted with a binary gradient (solvent A, 0.1% TFA in water; solvent B, 0.1% TFA in acetonitrile; Gradient, 0%–100% B over 20 min). Specific activity was calculated using the relation (% radiochemical yield × mCi present)/(mmol of peptide × 100%).

Indium-111-Labeled Human Polyclonal IgG. Human polyclonal IgG was derivatized with DTPA by means of the DTPA–carboxy-anhydride chelate method (19,20). Approximately two chelating groups were present per IgG. The conjugate was radiolabeled with 111In- by a previously reported method (21,22). Radiochemical purity was determined using ITLC-SG chromatographic strips developed with 0.1 M sodium citrate (pH 5.5); typically, >90% of the radioactivity was associated with antibody.

Indium-111-Labeled Leukocytes. Approximately 20 ml of heparinized blood was drawn from an ear artery of the infected rabbits, diluted 1:1 with Hespan and leukocytes were isolated by a previously described procedure (23,24) with the following modifications. The blood was sedimented for 45 min and leukocyte-rich plasma (LRP) was isolated. The LRP was centrifuged at 450 × g for 5 min and the leukocyte pellet was suspended in saline (10 ml) and allowed to stand at room temperature for 1 hr. The supernatant was removed and the cells were resuspended in fresh saline (5 ml). Indium-111-oxine (500 μCi) was added dropwise with agitation and the mixture was incubated at 37°C for 1 hr with intermittent agitation. The radiolabeled cells were allowed to sediment and the pellet was suspended in platelet poor plasma.

Indium-111-Labeled Red Blood Cells (RBCs). Approximately 5 ml of heparinized blood was drawn from an ear artery of the infected rabbits and centrifuged for 5 min at 1000 × g. The cells were washed with saline (10 ml, 3 times) and radiolabeled with 111In-oxine (500 μCi) as described above.

Infection Model. Male New Zealand white rabbits weighing 3.5–4.0 kg were used in all studies. E. coli from a single clinical isolate were grown overnight on trypticase soy agar plates and individual colonies were diluted with sterile normal saline to produce a turbid suspension containing about 2 × 10^11 organisms per ml. Radiopharmaceuticals were administered 24 hr after bacterial injection, when the animals were judged to have moderate infections by palpation.

Radiochemical Injection and Imaging Protocols
Comparison of Technetium-99m-N-For-MLFK-HYNIC with Nonspecific Agents. In this study the injection imaging properties of 99mTc-N-For-MLFK-HYNIC (specific activity > 10,000 mCi/μmol) were compared with 111In-DTPA, 111In-RBCs and 111In-IgG. Although radiolabeled DTPA and RBCs are not very useful clinically for accessing localization, they are valuable controls for the increases in tissue permeability and hyperemia that are present at inflammatory lesions. For these studies, groups of rabbits (n = 6) were injected with the following combinations of radiopharmaceuticals:

Group 1: 0.5 mCi of 99mTc-N-For-MLFK-HYNIC + 0.05 mCi of 111In-DTPA.
Group 2: 0.5 mCi of 99mTc-N-For-MLFK-HYNIC + 0.05 mCi of 111In-IgG.
Group 3: 0.5 mCi of $^{99m}$Tc-N-For-MLFK-HYNIC + 0.05 mCi of $^{111}$In-RBCs.

Comparison of Technetium-99m-N-For-MLFK-HYNIC with a Low-Affinity Chemotactic Peptide Receptor Agonist and an Antagonist. In this study the infection imaging properties of $^{99m}$Tc-N-For-MLFK-HYNIC were compared with $^{111}$In-WBCs, $^{99m}$Tc-N-Ac-MLFK-HYNIC (a low-affinity agonist) and $^{99m}$Tc-iBoc-MLFK-HYNIC (a moderate-affinity antagonist). Radiolabeled leukocytes were injected through a marginal ear vein and 5 min later $^{99m}$Tc-labeled peptide (specific activity > 10,000 Ci/mmol) was injected in the opposite ear. The radiolabeled WBCs served as a reference for verifying uniformity of infection intensity between animals and experimental groups. The following combinations of radiopharmaceuticals were studied:

Group 1: 0.5 mCi of $^{99m}$Tc-N-For-MLFK-HYNIC + 0.05 mCi of $^{111}$In-WBCs.

Group 2: 0.5 mCi of $^{99m}$Tc-N-Ac-MLFK-HYNIC + 0.05 mCi of $^{111}$In-WBCs.

Group 3: 0.5 mCi of $^{99m}$Tc-iBoc-MLFK-HYNIC + 0.05 mCi of $^{111}$In-WBCs.

Blockade of $^{99m}$Tc-N-For-MLFK-HYNIC Localization by a Chemotactic Peptide Antagonist. In this study the effect of coinjection of a chemotactic peptide antagonist on the infection imaging properties of $^{99m}$Tc-N-For-MLFK-HYNIC was evaluated. All animals were coinjected with $^{111}$In-WBCs. Radiolabeled leukocytes were injected through a marginal ear vein and 5 min later $^{99m}$Tc-labeled peptide (specific activity > 10,000 mCi/μmol) was injected in the opposite ear. The radiolabeled WBCs served as a reference standard for normalization of the peptide T/B ratios. The following groups of rabbits were studied:

Group 1: 0.5 mCi of $^{99m}$Tc-N-For-MLFK-HYNIC + 0.05 mCi of $^{111}$In-WBCs.

Group 2: 0.5 mCi of $^{99m}$Tc-N-For-MLFK-HYNIC + 0.05 mCi of $^{111}$In-WBCs + 1.0 mg of N-iBoc-MLFK.

Gamma Camera Imaging and Biodistribution

At 2–3 and 16–18 hr following injection of the radiopharmaceuticals, the animals were anesthetized with ketamine/xylazine (15.0 and 1.5 mg/kg) and anterior images were acquired using a large field-of-view gamma camera equipped with a parallel hole medium energy collimator. Indium-111 and $^{99m}$Tc images were acquired simultaneously with 15% windows centered on photo peaks at 140 KeV for $^{99m}$Tc and 247 KeV for $^{111}$In. Phantom studies were performed to calculate the amount of cross-over of 174 KeV photons of $^{111}$In into the $^{99m}$Tc window and these data were used to correct the $^{99m}$Tc images. Regions-of-interest were drawn over the area of infection and the contralateral normal muscle and T/B ratios were calculated. After acquiring the final images, the animals were killed with an overdose of sodium pentobarbital. The lesions were carefully dissected and 5–6 representative samples of infected muscle (≈1 g each) without associated pus were excised. Samples of uninfected muscle were excised from contralateral thigh muscle. Regions with purulent exudate were localized and samples of pus were removed with the blunt edge of a scalpel. The concentrations of radioactivity in the samples of tissue and pus was measured with a well scintillation gamma counter. For comparison with the imaging results, infected-to-normal muscle and pus-to-normal muscle ratios were calculated.

Statistical Analysis

The results of the imaging and biodistribution studies were evaluated statistically by ANOVA followed by Duncan’s new multiple range test (25). For the studies comparing the imaging properties of $^{99m}$Tc-For-MLFK-HYNIC with non-specific agents or other peptides and $^{111}$In-WBCs (Studies 1 and 2), two-way ANOVA with a linear model in which time after injection and radiopharmaceutical were the classification variables used: T/B = Time + Radiopharmaceutical + Time × Radiopharmaceutical. For evaluating the effect of a chemotactic peptide antagonist on $^{99m}$Tc-For-MLFK-HYNIC localization, the T/B ratios $^{99m}$Tc-For-MLFK-HYNIC in the presence and absence of antagonist were divided by the corresponding ratios for $^{111}$In-WBCs and the normalized values were analyzed by two-way ANOVA with the same linear model. For the biodistribution data, one-way ANOVA with radiopharmaceutical as the classification variable was used. All results were expressed as mean ± s.e.m.

RESULTS

Peptide Synthesis, Radiolabeling and in Vitro Characterization

The chemotactic peptides and their hydrazino nicotinamide derivatives were prepared in good yield and excellent chemical purity (>98%). All products were homogeneous on both TLC and HPLC. UV analysis showed maximum absorption bands at 268 and 315 nm. Amino acid and mass spectral analyses were consistent with the expected products. When radiolabeled with $^{99m}$Tc, typical specific activities were >10,000 mCi/μmol after HPLC purification. EC50 for binding to the chemotactrant receptor on human PMNs and superoxide generation are summarized in Table 1. No adverse effects were detected after intravenous administration of any of the peptides in the animals studied.

Comparison of Technetium-99m-N-For-MLFK-HYNIC with Nonspecific Agents

In this study the infection imaging properties of $^{99m}$Tc-N-For-MLFK-HYNIC were compared with $^{111}$In-DTPA, $^{111}$In-RBCs and $^{111}$In-IgG in groups of six rabbits. Figure 1 shows representative gamma camera images for all four radiopharmaceuticals ~17 hr after injection. These data clearly indicate that infection localization was best with the $^{99m}$Tc-labeled peptide. However, significant accumulations of $^{111}$In-IgG and $^{111}$In-RBCs were also detected. In contrast, at this imaging time, minimal accumulation of $^{111}$In-DTPA was observed.

Figure 2A summarizes the T/B ratios 2–3 and ~17 hr after injection for all animals studied. ANOVA demonstrated significant main effects of radiopharmaceutical (p < 0.001), time (p < 0.001) and radiopharmaceutical by time interaction (p < 0.001). Equivalence of the infections in all groups of animals was validated by inspection of the lesions after death and the fact that the T/B ratios for the $^{99m}$Tc-labeled peptide in Groups 1–3 were nearly identical (p = ns, data not shown). At both imaging times, $^{99m}$Tc-N-For-MLFK-HYNIC had a higher T/B ratio than any other agent (p < 0.001) and the ratio increased significantly between early and delayed imaging (p < 0.01). Indium-111 IgG had a significantly higher T/B ratio than $^{111}$In-DTPA (p < 0.05) and a slightly higher T/B ratio than $^{111}$In-RBCs (p = ns). Between early and delayed imaging, the T/B ratios for $^{111}$In-IgG and $^{111}$In-RBCs increased slightly; how-

<table>
<thead>
<tr>
<th>Peptide</th>
<th>Receptor Binding (EC50, nM)</th>
<th>SO+ release (EC50, nM)</th>
<th>Peptide class</th>
</tr>
</thead>
<tbody>
<tr>
<td>N-For-MLFK</td>
<td>2.0</td>
<td>20.0</td>
<td>Agonist</td>
</tr>
<tr>
<td>N-Ac-MLFK</td>
<td>830</td>
<td>&lt;10^3</td>
<td>Week agonist</td>
</tr>
<tr>
<td>N-iBoc-MLFK</td>
<td>150</td>
<td>&gt;10^4</td>
<td>Weak antagonist</td>
</tr>
</tbody>
</table>

*Superoxide.*
however, the differences were not significant. For $^{111}$In-DTPA, T/B was similar for early and delayed imaging (p = NS).

Figure 2B summarizes the infected-to-normal muscle and pus-to-normal muscle T/B ratios determined by direct radioactivity measurements on samples of excised tissue. Absolute tissue concentrations are shown in Table 2. For both ratios, ANOVA demonstrated highly significant main effects of radiopharmaceutical (p < 0.0001) and $^{99m}$Tc-N-For-MLFK-HYNIC had higher T/B than any of the other agents tested (p < 0.01).

The T/B for $^{111}$In-IgG was significantly higher than the ratios for $^{111}$In-DTPA (p < 0.01) and $^{111}$In-RBCs (p < 0.05). The T/B for $^{111}$In-RBCs was significantly higher than the ratio for $^{111}$In-DTPA (p < 0.05).

Comparison of Technetium-$^{99m}$Tc-N-For-MLFK-HYNIC with a Low-Affinity Chemotactic Peptide Receptor Agonist and an Antagonist

In this study, the infection imaging properties of $^{99m}$Tc-N-For-MLFK-HYNIC were compared with $^{99m}$Tc-N-Ac-MLFK-HYNIC [a low-affinity chemotactic peptide agonist, EC$_{50}$ (superoxide) = 1.0 mM, EC$_{50}$ (receptor binding) = 830 nM] and $^{99m}$Tc-N-iBoc-MLFK-HYNIC [a moderate-affinity receptor antagonist, EC$_{50}$ (superoxide) = 10.0 mM, EC$_{50}$ (receptor binding) = 150 nM]. All animals were coinjected with $^{111}$In-WBCs.

Figure 3 shows representative gamma camera images for all four radiopharmaceuticals ~17 hr after injection. These data indicate that infection localization was best with $^{99m}$Tc-N-For-MLFK-HYNIC. The next highest level of accumulation was detected with $^{99m}$Tc-N-iBoc-MLFK-HYNIC and $^{111}$In-WBCs. Low levels of accumulation were observed with $^{99m}$Tc-N-Ac-MLFK-HYNIC.

Figure 4A summarizes the T/B ratios 2–3 and ~17 hr after injection for all animals that were studied. ANOVA demonstrated significant main effects of radiopharmaceutical (p < 0.001), time (p < 0.001) and radiopharmaceutical by time interaction (p < 0.001). Equivalent of the infections in all groups of animals was validated by inspection of the lesions after death and the fact that the T/B ratios for $^{111}$In-WBCs in groups 1–3 were nearly identical (data not shown). At both imaging times, $^{99m}$Tc-N-For-MLFK-HYNIC had a higher T/B ratio than for any other agent (p < 0.001) and the ratio increased significantly between early and delayed imaging (p < 0.01). Indium-111-WBCs and the moderate-affinity antagonist had comparable T/Bs, which were higher than the low-affinity

---

**TABLE 2**

Concentrations (%ID/g) of Nonspecific Imaging Agents and Chemotactic Peptide Analogs in Normal Muscle, Infected Muscle and Pus

<table>
<thead>
<tr>
<th>Agent</th>
<th>Normal muscle</th>
<th>Infected muscle</th>
<th>Pus</th>
</tr>
</thead>
<tbody>
<tr>
<td>DTPA</td>
<td>0.00034 ± 0.000026</td>
<td>0.0041 ± 0.0015</td>
<td>0.00021 ± 0.000058</td>
</tr>
<tr>
<td>RBCs</td>
<td>0.0038 ± 0.00073</td>
<td>0.030 ± 0.0031</td>
<td>0.025 ± 0.0094</td>
</tr>
<tr>
<td>IgG</td>
<td>0.0016 ± 0.00067</td>
<td>0.023 ± 0.0045</td>
<td>0.030 ± 0.013</td>
</tr>
<tr>
<td>WBCs</td>
<td>0.0038 ± 0.0011</td>
<td>0.024 ± 0.0018</td>
<td>0.035 ± 0.0076</td>
</tr>
<tr>
<td>N-For-MLFK</td>
<td>0.0030 ± 0.00044</td>
<td>0.10 ± 0.0084</td>
<td>0.18 ± 0.034</td>
</tr>
<tr>
<td>N-iBoc-MLFK</td>
<td>0.0025 ± 0.00055</td>
<td>0.048 ± 0.010</td>
<td>0.089 ± 0.040</td>
</tr>
<tr>
<td>N-Ac-MLFK</td>
<td>0.0054 ± 0.00025</td>
<td>0.033 ± 0.0020</td>
<td>0.045 ± 0.0082</td>
</tr>
</tbody>
</table>

DTPA = diethylene triamine pentaacetic acid; RBC = red blood cell; IgG = immunoglobulin G; WBC = white blood cell.
agonist (p < 0.05). For \(^{111}\text{In-WBCs}\) and \(^{99m}\text{Tc-N-iBoc-MLFK-HYNIC}\), T/B increased between the early and delayed images (p < 0.05). In contrast, with \(^{99m}\text{Tc-N-Ac-MLFK-HYNIC}\), T/B did not change significantly between the two imaging times (p = ns). In other studies, it was demonstrated that \(^{99m}\text{Tc-N-Ac-MLFK-HYNIC}\) and \(^{99m}\text{Tc-N-iBoc-MLFK-HYNIC}\) had no effect on peripheral leukocyte levels even at high doses (data not shown).

Figure 4B summarizes the infected-to-normal muscle and pus-to-normal muscle T/B ratios determined by direct radioactivity measurements on samples of excised tissue. Absolute tissue concentrations are shown in Table 2. For both ratios, ANOVA demonstrated a highly significant main effect of radiopharmaceutical (p < 0.0001). The infected-to-normal muscle ratio for \(^{99m}\text{Tc-N-For-MLFK-HYNIC}\) was higher than the T/B ratio for any of the other agents (p < 0.01), and T/B for \(^{99m}\text{Tc-N-iBoc-MLFK-HYNIC}\) was higher than the ratios for N-Ac-MLFK-HYNIC (p < 0.01) and \(^{111}\text{In-WBCs}\) (p < 0.01). The pus-to-normal muscle ratio for \(^{99m}\text{Tc-N-For-MLFK-HYNIC}\) was significantly higher than the ratios for N-Ac-MLFK-HYNIC (p < 0.01) and \(^{111}\text{In-WBCs}\) (p < 0.01).

Blockade of Technetium-99m-N-For-MLFK-HYNIC Localization by a Chemotactic Peptide Antagonist

In this study the effect of coinjection of a chemotactic peptide antagonist on the infection imaging properties of \(^{99m}\text{Tc-N-For-MLFK-HYNIC}\) was evaluated. All animals were coinjected with \(^{111}\text{In-WBCs}\).

Figure 5 shows representative gamma camera images for Group 1 and 2 animals ~17 hr after injection. These data indicate that accumulation of \(^{99m}\text{Tc-N-For-MLFK-HYNIC}\) at the site of infection was significantly reduced by coinjection of a large dose of antagonist. In contrast, the antagonist did not have a significant effect on localization of \(^{111}\text{In-WBCs}\).

Figure 6 summarizes the T/B 2–3 and ~17 hr after injection for all animals studied. ANOVA demonstrated significant main effects of radiopharmaceutical (p < 0.001), time (p < 0.05) and radiopharmaceutical by time interaction (p < 0.001). At the early imaging time, coinjection of the antagonist did not have a significant effect on peptide localization. In contrast, a marked reduction in accumulation was observed at the late imaging.
time (p < 0.001). Coinjection of the antagonist did not have a significant effect on localization of 111In-WBCs at either imaging time (p = ns).

DISCUSSION

Indium-111- and 99mTc-labeled chemotactic peptides have been shown to be among the most promising new radiopharmaceuticals for infection imaging (7,8,10–13). In previous imaging studies with these reagents, it was assumed that the mechanism of infection/inflammation localization is mediated by high-affinity binding to For-MLF receptors on leukocytes. Although most of the imaging results have been consistent with this mechanism, direct proof has not been available. In this study, we have advanced the peptide–receptor interaction hypothesis to a more rigorous theoretical basis.

The results of the studies comparing a potent 99mTc-labeled chemotactic peptide agonist with agents that accumulate at inflammatory sites by nonspecific mechanisms clearly indicate that these processes make at most a minimal contribution to overall peptide localization. From the imaging studies, the degree of localization of the four agents could be ordered as follows: 99mTc-peptide >> 111In-IgG > 111In-RBC >> 111In-DTPA. The biodistribution demonstrated a similar pattern of pus-to-normal tissue ratios. In contrast, the infected-to-normal tissue ratio for 111In-DTPA was greater than 111In-RBCs and similar to 111In-IgG. However, this difference was not considered to be of importance because absolute accumulation was extremely low (Table 2).

The imaging and biodistribution studies with a low-affinity agonist (N-Ac-MLFK) and a moderate-affinity antagonist (N-iBoc-MLFK) lend further support to a receptor-mediated mechanism for peptide localization. It is of interest that the EC50 for For-MLF receptor binding of N-Ac-MLFK is considerably lower than the previously reported value for N-Ac-MLF (3). This difference could be related to the difference in net charge on the peptide and requires further investigation. Despite the fact that only a limited number of compounds were studied, the results clearly indicate that there is a correlation between T/B ratio at injection sites and affinity for For-MLF receptors on leukocytes (1/EC50). In the future, studies with agonists and antagonists with a wider range of EC50s will be useful for further confirmation of this correlation. The greater magnitude of the pus-to-infected muscle ratios compared with infected-to-normal muscle ratios for all of the peptides (similar to 111In-WBCs) is further evidence for WBC-mediated localization. The most compelling evidence for receptor-mediated localization are the results of the blocking studies. These investigations clearly established that coinjection of a large excess of unlabeled antagonist with a potent 99mTc-labeled chemotactic peptide agonist results in a significant reduction in T/B for peptide localization but does not have a significant effect on T/B for 111In-leukocytes. Autoradiographic studies might be useful to demonstrate displacement at the cellular level.

The fact that these studies were performed with a rabbit model of focal infection suggests the need for some caution in interpreting the results. Previous studies have demonstrated that rabbit and rodent leukocytes have different pharmacokinetic properties than human cells. Although it is true that T/B ratios for 111In-WBCs tend to be lower in infections in rabbits compared with infections of comparable severity in dogs, we have demonstrated that the overall patterns of 99mTc-peptide accumulation are similar in rabbits and dogs (26). These data indicate that the rabbit model is a useful preparation for initial screenings of new reagents. Clearly, when an optimal reagent is developed, further studies in dogs or monkeys should be performed.

Overall, the results of these studies establish three important points:

1. The increased tissue permeability and blood volume of inflammatory lesions cannot explain the degree of infection localization observed with radiolabeled chemotactic peptides. Also, previous results from our laboratory have demonstrated that increased blood flow is not an important factor (27).

2. The infection localization properties of chemotactic peptides are related to the affinity for For-MLF receptor binding.

3. Receptor antagonists localize at sites of infection to a significant degree. If high-affinity antagonists are developed, they could be the optimal infection imaging agents.

Our imaging studies with a 99mTc-labeled receptor antagonist is the first demonstration of infection imaging with a chemotactic peptide analog that lacks biological activity. Although the EC50 of the peptide analog that was tested may not be optimal for clinical imaging, the observation is extremely important since it opens a new pathway for development of convenient reagents for clinical imaging. Previously, we demonstrated that potent chemotactic peptide agonists could be radiolabeled at specific activities that result in doses of unlabeled peptide that are well below the concentrations that induce significant reduction in peripheral leukocyte levels in rabbits, dogs or monkeys (9,12,27). However, these radiolabeling procedures are relatively complex and require controlled generator elution and HPLC purification. Clearly, elimination of these requirements would be of great value for the widespread application of chemotactic peptide-based infection imaging reagents. In addition to the development of antagonists, another factor that can affect the imaging properties of chemotactic peptide infection imaging agents is the choice of the coligand that is used for radiolabeling. Although the choice of coligand has not been shown to effect receptor binding or biological activity, it can have profound influences on the pattern biodistribution to uninfected tissues (28). Currently, one of the main focuses of research in our laboratory is the development of high-affinity antagonist/coligand combinations.
CONCLUSION

We have demonstrated that nonspecific mechanisms contribute minimally to the localization of 99mTc-chemotactic peptide analogs at sites of infection and the majority of accumulation appears to be receptor mediated. Also, we have demonstrated that chemotactic peptide receptor antagonists can be used for infection imaging. These results put the receptor hypothesis for chemotactic peptide localization on firmer theoretical ground and provide important new insights for the future development of improved radiopharmaceuticals.

ACKNOWLEDGEMENTS

This work was supported in part by National Institutes of Health grants 5P50 GM21700 and RO1 A131094.

REFERENCES


EDITORIAL

Technetium-99m-Labeled Chemotactic Peptides: Specific for Imaging Infection?

In 1991, Fischman et al. (1) were the first to report the potential diagnostic use of 111In-labeled chemotactic peptide analogs of N-formyl-methionyl-leucyl-phenylalanine (ForMLF), a bacterial product for imaging infection. Subsequently, Babich et al. (2,3) reported that in the same rat model, 99mTc-labeled hydrazinonicotinamide (HYNIC) derivatized chemotactic peptides also localize at the site of infection. They identified that N-formyl-methionyl-leucyl-phenylalanine-lysine (FMLK) conjugated to HYNIC and labeled with 99mTc had the most favorable distribution characteristics for infection imaging. While these reports clearly documented the uptake of radiolabeled peptides at the infection site, the specificity of these tracers for infection and the exact mechanism(s) of localization are not well understood. It was assumed that the mechanism of uptake of chemotactic peptides in the infection/inflammation foci is mediated by high-affinity binding to ForMLF receptors on leukocytes.

In this issue, Babich et al. (4) and van der Laken et al. (5), report that 99mTc-labeled chemotactic peptides specifically localize at the site of infectious foci in a rabbit model of acute infection. Despite the differences in experimental design, the two investigators studied the infection uptake and specificity of the same radiotracer, the high-affinity chemotactic peptide agonist 99mTc-FMLK-HYNIC. While the results reported in these two articles are encouraging for further work, it is important to analyze the differences of evidence presented here to demonstrate the in vivo specificity of 99mTc peptides for infection.

Babich et al. (6) performed three studies in rabbits with E. Coli infection. The first compares the infection/background or target-to-background ratios (T/B) of 99mTc-FMLK-HYNIC with that of 111In-labeled DTPA, RBC and IgG. Since the RBCs and IgG remain in circulation longer than the peptide, T/B ratios are expected to be lower than the labeled peptides. Imaging studies at 2–3 hr, however, show that T/B ratios of all three tracers are between 2.0–3.0. The most striking difference is seen only at 16–18 hr.